{"id":821600,"date":"2025-03-04T16:11:33","date_gmt":"2025-03-04T21:11:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/"},"modified":"2025-03-04T16:11:33","modified_gmt":"2025-03-04T21:11:33","slug":"allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/","title":{"rendered":"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity"},"content":{"rendered":"

<\/p>\n

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity<\/b><\/p>\n

Patent portfolio now exceeds 60 issued patents globally<\/i><\/p>\n

NATICK, Mass.–(BUSINESS WIRE<\/a>)–
\nAllurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled \u201cAutomatic-Sealing Balloon-Filling Catheter System\u201d and U.S. Patent No. 12,245,962 titled \u201cBalloon Sealing and Fill Valve\u201d. These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion\u2019s proprietary Balloon technology for the treatment of obesity that includes an enhanced valve for Balloon filling and an innovative mechanism that controls balloon opening. These patents are expected to provide protection through April 2043. With the issuance of these patents, the Company now has 22 patents issued in the U.S. and 64 patents issued globally.\n<\/p>\n

\nThe Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world\u2019s first and only swallowable, procedure-lessTM<\/sup> gastric balloon for weight loss with the Allurion Virtual Care Suite, including the Allurion Mobile App and Connected Scale for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform. Patients on the Allurion Program lose 10-15% of their total body weight and in certain studies have been shown to increase their muscle mass.1<\/sup><\/p>\n

\nShantanu Gaur, Allurion\u2019s Founder and CEO, noted, \u201cWith the issuance of these two patents, we now have amassed 22 issued patents in the U.S. and 64 issued patents globally. As we embark on new clinical trials that seek to combine the Allurion Balloon with GLP-1 therapy, we intend to continuously enhance the design and manufacture of the Allurion Balloon and move toward a new gold standard for the treatment of obesity.\u201d\n<\/p>\n

About Allurion<\/b><\/p>\n

\nAllurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world\u2019s first and only swallowable, procedure-lessTM<\/sup> gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.\n<\/p>\n

\nFor more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201ctarget,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions and include statements regarding the expected protection and enhancement of Allurion\u2019s products and services and the intellectual property rights therein, the ability to enhance the design and manufacture of the Allurion Balloon and the global footprint of our patent portfolio so that our products can serve patients around the world, our ability to improve existing technologies and introduce new product features, market acceptance of such improved and new technologies and features, the success of our commercialization efforts, the uniqueness of Allurion\u2019s product and service offerings and other statements about future events that reflect the current beliefs and assumptions of Allurion\u2019s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion\u2019s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this press release, including but not limited to (i) the ability of Allurion to obtain regulatory approval for and successfully commercialize the Allurion Program, (ii) the timing of and results from its clinical studies and trials, (iii) the evolution of the markets in which Allurion competes and the rise of GLP-1 drugs, (iv) the ability of Allurion to defend its intellectual property and satisfy regulatory requirements, (v) the impact of the COVID-19 pandemic, Russia-Ukraine war and Israel-Hamas war on Allurion\u2019s business, (vi) Allurion\u2019s expectations regarding its market opportunities, (vii) the outcome of any legal proceedings against Allurion, (viii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates, and (ix) uncertainties related to market conditions and the completion of the private placement on the anticipated terms or at all. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K filed on March 26, 2024 and Amendment No. 1 thereto filed on April 29, 2024, the Company\u2019s Quarterly Report on Form 10-Q filed on November 13, 2024 and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.\n<\/p>\n

1<\/sup> Dejeu et al. Clin. Pract.<\/i>2024<\/b>, 14<\/i>(3), 765-778; https:\/\/doi.org\/10.3390\/clinpract14030061<\/b><\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250304954371\/en\/<\/a><\/span><\/p>\n

Global Media and Investor Inquiries
\n<\/b>
Hannah Lindberg
\n
hlindberg@allurion.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Medical Devices Health Pharmaceutical Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity Patent portfolio now exceeds 60 issued patents globally NATICK, Mass.–(BUSINESS WIRE)– Allurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled \u201cAutomatic-Sealing Balloon-Filling Catheter System\u201d and U.S. Patent No. 12,245,962 titled \u201cBalloon Sealing and Fill Valve\u201d. These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion\u2019s proprietary Balloon technology for the treatment of obesity that includes … <\/p>\n

Continue reading “Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-821600","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAllurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity Patent portfolio now exceeds 60 issued patents globally NATICK, Mass.–(BUSINESS WIRE)– Allurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled \u201cAutomatic-Sealing Balloon-Filling Catheter System\u201d and U.S. Patent No. 12,245,962 titled \u201cBalloon Sealing and Fill Valve\u201d. These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion\u2019s proprietary Balloon technology for the treatment of obesity that includes … Continue reading "Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-04T21:11:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity\",\"datePublished\":\"2025-03-04T21:11:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/\"},\"wordCount\":1037,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/\",\"name\":\"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-03-04T21:11:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/","og_locale":"en_US","og_type":"article","og_title":"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity - Market Newsdesk","og_description":"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity Patent portfolio now exceeds 60 issued patents globally NATICK, Mass.–(BUSINESS WIRE)– Allurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S. Patent and Trademark Office (USPTO) dated February 19, 2025 for U.S. Patent No. 12,246,163 titled \u201cAutomatic-Sealing Balloon-Filling Catheter System\u201d and U.S. Patent No. 12,245,962 titled \u201cBalloon Sealing and Fill Valve\u201d. These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion\u2019s proprietary Balloon technology for the treatment of obesity that includes … Continue reading \"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-04T21:11:33+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity","datePublished":"2025-03-04T21:11:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/"},"wordCount":1037,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/","name":"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-03-04T21:11:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250304954371r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-notification-of-issuance-of-new-u-s-patents-on-next-generation-weight-loss-device-for-the-treatment-of-obesity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=821600"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821600\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=821600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=821600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=821600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}